Imedex® is an industry leader in providing accredited, independent continuing medical education to health care professionals.

Cancelled

Continuing Medical Education

Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex®, LLC designates this live educational activity for a maximum 7.0 of AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Who Should Attend

This educational activity is specifically designed for community oncologists, medical oncologists, radiation oncologists, surgical oncologists, pathologists, hospitalists, internal medicine specialists, and other health-care professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physicians' assistants, etc.) involved and/or interested in the therapeutic management of patients with breast cancer.

Objectives

After successful completion of this course, participants should be able to:

  • Assess the utility of genetic profiling in guiding treatment decisions for estrogen receptor–positive (ER+) breast cancer
  • Optimize neoadjuvant and adjuvant treatment strategies for early hormone receptor–positive (HR+) and/or HER2+ breast cancers
  • Review the latest data on novel agents for HR+, HER2+, and/or triple-negative metastatic breast cancers, as well as how best to integrate novel and standard therapies
  • Formulate treatment strategies for challenging scenarios across subtypes of HR+, HER2+, and/or triple-negative breast cancers
  • Evaluate evidence on both sides of recent breast cancer controversies, including neoadjuvant and adjuvant therapies for ER+ disease, genetic profiling for node-positive disease, and duration of hormone therapy for luminal B cancers
  • Review new data on HR+, HER2+, and triple-negative breast cancers from recent and upcoming research meetings, and discuss their potential impact on clinical practice